Antispasmodics Drugs Market Report 2026

Antispasmodics Drugs Market Overview

• Antispasmodics Drugs market size has reached to $14.93 billion in 2025 • Expected to grow to $23.47 billion in 2030 at a compound annual growth rate (CAGR) of 9.5% • Growth Driver: Elderly Population Boom Fuels Growth In Antispasmodic Drug Market • Market Trend: Product Launches For Overactive Bladder • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Antispasmodics Drugs Market?

Antispasmodic drugs are medications that treat, prevent, or reduce the frequency of muscular spasms, particularly those of smooth muscle, such as those in the gut wall. It works by slowing the normal motions of the gut and relaxing the muscles of the stomach and intestines. The main drugs involved in antispasmodics drugs are dicyclomine hydrochloride, loperamide hydrochloride and others. Dicyclomine refers to an anticholinergic medicine that reduces gastrointestinal muscular spasms by inhibiting the activity of a natural chemical in the body. The indications involved are irritable bowel syndrome, stomach cramps, and others that are administered by oral, parenteral and other modes. The distribution channels involved are hospital pharmacies, online pharmacies, and retail pharmacies with end-users such as hospitals, homecare, specialty clinics, and others.

What Is The Antispasmodics Drugs Market Growth Forecast?

The antispasmodics drugs market size is expected to see strong growth in the next few years. It will grow to $23.47 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to advancements in precision medicine, development of injectable and liquid antispasmodics, expansion of online pharmacy platforms, growing geriatric and pediatric patient population, integration of digital health monitoring systems. Major trends in the forecast period include personalized antispasmodic therapy, advanced drug delivery systems, increasing prevalence of gastrointestinal disorders, growing homecare medication adoption, rising focus on pediatric and geriatric patients.

Global Antispasmodics Drugs Market Segmentation

1) By Drug: Dicyclomine Hydrochloride, Loperamide Hydrochloride, Other Drugs 2) By Indication: Irritable Bowel Syndrome, Stomach Cramps, Other Indications 3) By Route Of Administration: Oral, Parenteral, Other Modes Of Administrations 4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Dicyclomine Hydrochloride: Oral Tablets, Injectable Formulations 2) By Loperamide Hydrochloride: Oral Tablets, Liquid Formulations 3) By Other Drugs: Hyoscine Butylbromide (Scopolamine), Peppermint Oil, Atropine, Other Antispasmodics

What Are The Drivers Of The Antispasmodics Drugs Market?

An increasing elderly population is expected to propel the growth of the antispasmodic drug market going forward. People of 65 years and older are considered to be elderly and are associated with a host of physical and psychological health issues. Antispasmodic drugs are helpful for elderly populations in managing symptoms related to various conditions that can cause muscle spasms or cramping and also could be used for some conditions like irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million people aged 65 or older in the UK. This number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, an increase in the elderly population will drive the antispasmodic drug market. The increasing prevalence of irritable bowel syndrome (IBS) is expected to propel the growth of the antispasmodic drug market going forward. Irritable Bowel Syndrome (IBS) is a common digestive disorder characterized by a group of symptoms that affect the large intestine (colon), which cause discomfort and disrupt the normal functioning of the digestive system. Antispasmodic drugs are used for the treatment of irritable bowel syndrome (IBS) to target and alleviate muscle spasms and cramps in the gastrointestinal tract, providing relief from abdominal pain and discomfort to patients. For instance, in June 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency, the estimated prevalence of inflammatory bowel disease (IBD) in the U.S. ranges from 2.4 to 3.1 million, exhibiting variations in impact among different groups. Also, Oxford University Press, a UK-based publishing company, estimates that in 2023, 322,600 Canadians are living with inflammatory bowel disease (IBD). Therefore, the increasing prevalence of irritable bowel syndrome (IBS) drives the growth of the antispasmodic drug market.

Key Players In The Global Antispasmodics Drugs Market

Major companies operating in the antispasmodics drugs market are Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd.

Global Antispasmodics Drugs Market Trends and Insights

Major companies operating in the antispasmodics drugs market are launching new products to sustain their position in the market. For instance, in January 2023, Lupin Limited, an Indian-based pharmaceutical company, launched Fesoterodine Fumarate, approved by the Food and Drug Administration (FDA), a US-based federal government agency. Fesoterodine fumarate is a generic antispasmodic drug used to treat certain bladder problems, such as overactive bladder and neurogenic detrusor overactivity. Fesoterodine fumarate belongs to the class of drugs known as antispasmodics and works by relaxing the bladder muscles. It is available in the form of extended-release tablets.

Regional Insights

North America was the largest region in the antispasmodics drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Antispasmodics Drugs Market?

The antispasmodics drugs market consists of sales of natural alkaloids such as atropine, belladonna, hyoscyamine, scopolamine, and related drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antispasmodics Drugs Market Report 2026?

The antispasmodics drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antispasmodics drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.